Business
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
TSX Exchange Symbol: RVX CALGARY , June 8, 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) ...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\nTSX Exchange Symbol: RVX\n\n\n\nCALGARY, June 8, 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) today announced that findings of a study performed by the Baker IDI Heart and Diabetes Institute, Melbourne, Australia and Resverlogix's scientists were reported at the 2015 ADA Scientific Sessions in Boston, MA.  The presentation was entitled \"Effects of the ApoA-I Inducer, RVX-208 on Glucose Metabolism in Individuals with Prediabetes Mellitus.\"  The data in the presentation was based on patients with prediabetes mellitus who already had abnormal blood glucose levels. Treatment with RVX-208 (200 mg/day) for 29-33 days led to not only a reduction in glucose absorption but also suppression of endogenous glucose production. The significance of these findings are as follows: (1) short duration of RVX-208 treatment had effects on glucose metabolism, and (2) both the reduction in glucose absorption and production are expected to be of benefit in patients with prediabetes mellitus. \n\nThe above findings are intriguing when viewed in the light of additional new data arising from the same study reported at the recent International Society of Atherosclerosis (ISA) meeting, May 23-26, 2015 in Amsterdam, NL.  At the ISA meeting, a presentation entitled, \"The effects of a novel apoA-I transcriptional regulator (RVX-208) on whole plasma and HDL lipidomes,\" the same team of investigators detailed the ability of RVX-208 to change the lipid profile within the high-density lipoprotein (HDL) favouring normalization of the composition towards that observed in healthy individuals. Together, the data contained in the two presentations add to the idea that RVX-208 has the ability to affect glucose and lipid metabolism in ways that will be of benefit to patients with high cardiovascular disease (CVD) risks.\n\n\"The results arising from the study are enlightening because they show the effects of RVX-208, a selective bromodomain extra-terminal (BET) protein inhibitor, on glucose and lipids in patients with prediabetes mellitus,\" stated Dr. Norman Wong, chief scientific officer, Resverlogix.  \"As a physician who practices endocrinology, these findings give rise to added benefits of RVX-208 for patients who have CVD risks on top of metabolic abnormalities involving glucose and lipids. The findings also serve to introduce the idea...